Cargando…
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
BACKGROUND: The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL numbers. Nonetheless, a significant proportion of patients with pre-existing immu...
Autores principales: | Bretz, Anne Catherine, Parnitzke, Ulrike, Kronthaler, Kerstin, Dreker, Tobias, Bartz, René, Hermann, Frank, Ammendola, Astrid, Wulff, Tanja, Hamm, Svetlana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839078/ https://www.ncbi.nlm.nih.gov/pubmed/31703604 http://dx.doi.org/10.1186/s40425-019-0745-3 |
Ejemplares similares
-
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
por: Wobser, Marion, et al.
Publicado: (2019) -
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma
por: Streubel, Gundula, et al.
Publicado: (2021) -
HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022) -
The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression
por: Srinivas, Nalini, et al.
Publicado: (2023) -
Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)